New drug aims to reverse bone marrow scarring in rare blood cancer
NCT ID NCT07394153
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 4 times
Summary
This phase 2 trial tests the drug pacritinib in 30 people with myelofibrosis, a rare bone marrow cancer, who also have low platelet counts. The goal is to see if pacritinib can reduce scarring (fibrosis) in the bone marrow and improve symptoms. Participants take pacritinib pills twice daily for up to two years, with regular check-ups and scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pacritinib
- What this could lead to
- If successful, this could show that pacritinib reduces bone marrow scarring and improves blood cell counts in myelofibrosis patients with low platelets.
- What could go wrong
- This is a small, early-phase study with only 30 participants and no comparison group. The drug may cause side effects or fail to improve fibrosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fundación Jimenez Díaz
RECRUITINGMadrid, Madrid, 28040, Spain
-
Hospital Clinic de Barcelona
RECRUITINGBarcelona, Barcelona, 08036, Spain
-
Hospital Clínico Universitario Valencia
RECRUITINGValencia, Valencia, 46010, Spain
-
Hospital General Universitario Gregorio Marañon
RECRUITINGMadrid, Madrid, 28007, Spain
-
Hospital General Universitario Morales Meseguer
RECRUITINGMurcia, Murcia, 30008, Spain
-
Hospital General Universitario de Valencia
RECRUITINGValencia, Valencia, 46014, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Madrid, 28041, Spain
-
Hospital Universitario Doctor Peset
NOT_YET_RECRUITINGValencia, Valencia, 46017, Spain
-
Hospital Universitario Ramon y Cajal
RECRUITINGMadrid, Madrid, 28034, Spain
-
Hospital Universitario Vall d´Hebron
RECRUITINGBarcelona, Barcelona, 08035, Spain
-
Hospital Universitario de Jerez
RECRUITINGJerez de la Frontera, Cádiz, 11407, Spain
-
Hospital Universitario de Salamanca
NOT_YET_RECRUITINGSalamanca, Salamanca, 37007, Spain
-
Hospital del Mar Barcelona
RECRUITINGBarcelona, Barcelona, 08003, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- Can a new pill tame myelofibrosis?
- MRI as a window into bone marrow disease: a new biomarker test?
- Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
- Can a drug free myelofibrosis patients from frequent blood transfusions?